Lauriane Hamard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lauriane Hamard has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Denise Nardelli-Haefliger
Department of Urology, Lausanne University Hospital, 1011 Lausanne, Switzerland
2 shared publications - Florian Alonso
Laboratory for the Bioengineering of Tissues (BioTis-INSERM U1026), Université de Bordeaux, 33607 Bordeaux, France
2 shared publications - Jacques-Antoine Haefliger
Department of Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland
2 shared publications - Karthik Sathiyanadan
Department of Urology, Lausanne University Hospital, 1011 Lausanne, Switzerland
2 shared publications - Paolo Meda
Department of Cell Physiology and Metabolism, Medical Center, University of Geneva, 1206 Geneva, Switzerland
2 shared publications - Sonia Domingos-Pereira
Department of Urology, Lausanne University Hospital, 1011 Lausanne, Switzerland
2 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2494
Correction: Sathiyanadan et al. Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. Int. J. Mol. Sci. 2022, 23, 2930
- 9 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2494
Open AccessCorrection: Sathiyanadan et al. Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. Int. J. Mol. Sci. 2022, 23, 2930
- Open Access
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2930
Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth
Connexin37 (Cx37) and Cx40 form intercellular channels between endothelial cells (EC), which contribute to the regulation of the functions of vessels. We previously documented the participation of both Cx in developmental angiogenesis and have further shown that loss of Cx40 decreases the growth of different tumors. Here, we report that loss of Cx37 reduces (1) the in vitro proliferation of primary human EC; (2) the vascularization of subcutaneously implanted matrigel plugs in Cx37−/− mice or in WT using matrigel plugs supplemented with a peptide targeting Cx37 channels; (3) tumor angiogenesis; and (4) the growth of TC-1 and B16 tumors, resulting in a longer mice survival. We further document that Cx37 and Cx40 function in a collaborative manner to promote tumor growth, inasmuch as the injection of a peptide targeting Cx40 into Cx37−/− mice decreased the growth of TC-1 tumors to a larger extent than after loss of Cx37. This loss did not alter vessel perfusion, mural cells coverage and tumor hypoxia compared to tumors grown in WT mice. The data show that Cx37 is relevant for the control of EC proliferation and growth in different tumor models, suggesting that it may be a target, alone or in combination with Cx40, in the development of anti-tumoral treatments.
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2930
Open AccessTargeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth
Connexin37 (Cx37) and Cx40 form intercellular channels between endothelial cells (EC), which contribute to the regulation of the functions of vessels. We previously documented the participation of both Cx in developmental angiogenesis and have further shown that loss of Cx40 decreases the growth of different tumors. Here, we report that loss of Cx37 reduces (1) the in vitro proliferation of primary human EC; (2) the vascularization of subcutaneously implanted matrigel plugs in Cx37−/− mice or in WT using matrigel plugs supplemented with a peptide targeting Cx37 channels; (3) tumor angiogenesis; and (4) the growth of TC-1 and B16 tumors, resulting in a longer mice survival. We further document that Cx37 and Cx40 function in a collaborative manner to promote tumor growth, inasmuch as the injection of a peptide targeting Cx40 into Cx37−/− mice decreased the growth of TC-1 tumors to a larger extent than after loss of Cx37. This loss did not alter vessel perfusion, mural cells coverage and tumor hypoxia compared to tumors grown in WT mice. The data show that Cx37 is relevant for the control of EC proliferation and growth in different tumor models, suggesting that it may be a target, alone or in combination with Cx40, in the development of anti-tumoral treatments.